http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2402320-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3fffbc4ad2f8feb618a512ee1463ab6c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6837 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6841 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2001-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b928f0b294ceb88b5b68a3d8106dfdec |
| publicationDate | 2001-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2402320-A1 |
| titleOfInvention | Patient stratification for cancer therapy based on genomic dna microarray analysis |
| abstract | The method of the invention comprises the stratification of a cancer patient population into various cancer therapy groups based on analysis by genomic D NA microarray of multiple gene amplifications or deletions present or absent in the diseased tissue of each patient. In particular, the invention involves patient stratification into one of at least four cancer therapy groups based on the microarray analysis of gene amplification or gene deletion at multipl e chromosome locations. The invention has the significant clinical advantage o f guiding selection of expensive cancer adjuvant drugs for use with patients most likely to respond positively to the individual drug. For example, a genomic DNA microarray simultaneously measuring 59 separate gene amplifications or gene deletions in diseased tissue can be used to stratify solid tumor cancer patients, such as breast cancer patients, into at least nine groups: those most likely to respond to (i) anti-HER-2/neu therapy (Herceptin.RTM.), (ii) anti-EGFR therapy (C225 antibody), (iii) anti-AKT1 therapy (cis-platin), (iv) anti-PIK3CA therapy, (v) anti-thymidylates syntha se therapy (5-fluorouracil), (iv) anti-Topoisomerase II therapy (doxorubicin), (vii) anti-cmyc therapy, (viii) combination of anti-HER-2 therapy and anti- AKT1 therapy, and (ix) combination of anti-EGFR and anti-AKT1 therapy. The invention has the further advantage of identifying patients most likely to respond synergistically to a particular combination of adjuvant therapies.</ SDOAB> |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010121380-A1 |
| priorityDate | 2000-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 945.